Launching Penn Medicine London

Continuing its mission of high-quality patient care, cutting-edge research and innovation, and training the world’s doctors, Penn Medicine has announced it is expanding to the United Kingdom. The new Penn Medicine London officially opened in the city’s Mayfair area on November 19. The initiative, the first of its kind for Penn, provides a path for UK and EU patients to access Penn’s world-class experts and care through referrals and telemedicine, as well as opportunities for collaboration with UK medical schools.

“Penn Medicine has a long history—dating past the founding of our nation­—as a global health-care leader, and we are pleased to extend our reach with a physical presence in the UK,” said Ralph Muller, CEO of the University of Pennsylvania Health System. “We have always been proud of our role in training the world, and this initiative advances that mission by opening new doors and forging new relationships both in the UK and across Europe.”

Penn Medicine’s expertise is especially highlighted by its role as a global pioneer in new approaches to cancer treatment, particularly in personalized cellular therapies and proton beam radiation. Penn developed the first US Food and Drug Administration-approved chimeric antigen receptor T cell (CAR T) therapy, which was recently approved by the European Commission (EC) for treating two aggressive forms of cancer. The approach has successfully eradicated blood cancer in hundreds of patients around the world, including in the UK. Studies show it leads to overall remission rates of 80% among acute lymphoblastic leukemia (ALL) patients whose cancer could not be contained by the standard chemotherapies doctors have relied on for decades.

Penn is also home to many other “firsts” that have paved the way for modern medicine across the globe, from founding the nation’s first medical school to performing the world’s first x-ray and discovering the first gene linked to cancer. Each day, Penn physicians and scientists propel medical science forward in hundreds of laboratories, and with mobile apps and big data.

“Penn Medicine London will provide enhanced access for patients seeking care from teams who are continuing to pioneer the next generation of prevention and treatment strategies for diseases of all kinds,” said J. Larry Jameson, executive vice president of the University of Pennsylvania for the Health System and dean of Penn’s Perelman School of Medicine. “The initiative also provides opportunities for innovative collaborations between Penn and UK and EU medical schools, including research-focused projects as well as physician exchange programs, ensuring the world’s brightest medical minds continue to share ideas and learn from each other.”

To mark the opening of its first enterprise in the UK, Penn Medicine hosted an event in London for friends and partners to gather and learn about what the institution will bring to the UK.